• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

GHB, or gamma-hydroxybutyrate, is a treatment used for the management of cataplexy. However, it has also gained negative publicity as a drug of misuse and has been linked to various social and legal problems. As a result, many countries have established rules to control the distribution of GHB.

In the U.S., GHB was listed as a most restrictive classification in 1990, which is the most restrictive classification according to US federal law. However, in 2002, GHB was rescheduled to Schedule I to Schedule III, which allowed for specific therapeutic uses, including the management of cataplexy. This change in classification status was made due to the development of new models and the implementation of safety measures to minimize the risk of substance abuse.

In the Britain, GHB is classified as a Schedule B substance under the Misuse of Drugs Act 1971, which means that possessing GHB without a valid license can result in sentence. Class C substances are considered to be the lesser serious of the controlled substances, but offences involving GHB can still carry consequences of up to 14 years in prison.

In Canada, GHB was listed as a most restrictive classification under the Controlled Drugs and Substances Act in 2003, which gave the Canadian government the power to regulate its sale. In order to obtain ghb droge kaufen, Canadians typically require a license from a licensed medical practitioner, which is necessary for valid treatment of cataplexy.

In Australia, GHB is classified as a strict control, which is the most restrictive scheduling category under state and federal laws. This classification restricts the possession of GHB except for therapeutic purposes, and possession without a license can lead to lengthy prison sentences.

In Germany, GHB is classified as a Betäubungsmittel Tier 2 substance, which places it under greater restrictions than substances classified as Tier 3 but lesser restrictions than Tier 1 substances. The possession of GHB in Germany requires a permit from the regulatory authorities, and illicit use can result in penalties and imprisonment.

In European Union, GHB is considered a harmful substance under the Loi du 31 décembre 1970, which means that it has great health risks, and as such is controlled and available by prescription and license, outside specific use, possible penalties of arrest as recidivists 5 years may be handed. In the Swedes, it is classified as a "strong drug" which essentially gives the same restrictive use such as drugs.

It is essential to note that the ever-shifting political and climate often gives health organizations and legal regulatory commissions much to debate. Under such deliberations GHB, often for therapeutic purposes is discovered to be of increasingly use, and also, that many current restrictions can often be proven to be ultimately ineffective. As existing research and findings evolve around GHB they find evidence supporting GHB's range in potential therapeutic uses worldwide, a discussion ultimately that calls for continued reflection and communications in society, including strictness and reform as appropriate legal responses.